REUTERS: AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures.The approval of Skyrizi, an injectable drug, is based on results from AbbVie's global Phase 3 psoriasis program, which assessed the safety and efficacy of the drug in adults with moderate to severe plaque psoriasis.
Humira is the world's best-selling prescription medicine and has long buoyed AbbVie's business, bringing in revenue of US$19.94 billion in 2018. But it is set to face biosimilar competition from 2023.Skyrizi, which won regulatory approval in Canada and Japan earlier this year, is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of the drug.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »